Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Respiratory Research
Published in: Respiratory Research 1/2011

Open Access 01-12-2011 | Review

Analysing the eosinophil cationic protein - a clue to the function of the eosinophil granulocyte

Authors: Jonas Bystrom, Kawa Amin, David Bishop-Bailey

Published in: Respiratory Research | Issue 1/2011

Login to get access

Abstract

Eosinophil granulocytes reside in respiratory mucosa including lungs, in the gastro-intestinal tract, and in lymphocyte associated organs, the thymus, lymph nodes and the spleen. In parasitic infections, atopic diseases such as atopic dermatitis and asthma, the numbers of the circulating eosinophils are frequently elevated. In conditions such as Hypereosinophilic Syndrome (HES) circulating eosinophil levels are even further raised. Although, eosinophils were identified more than hundred years ago, their roles in homeostasis and in disease still remain unclear. The most prominent feature of the eosinophils are their large secondary granules, each containing four basic proteins, the best known being the eosinophil cationic protein (ECP). This protein has been developed as a marker for eosinophilic disease and quantified in biological fluids including serum, bronchoalveolar lavage and nasal secretions. Elevated ECP levels are found in T helper lymphocyte type 2 (atopic) diseases such as allergic asthma and allergic rhinitis but also occasionally in other diseases such as bacterial sinusitis. ECP is a ribonuclease which has been attributed with cytotoxic, neurotoxic, fibrosis promoting and immune-regulatory functions. ECP regulates mucosal and immune cells and may directly act against helminth, bacterial and viral infections. The levels of ECP measured in disease in combination with the catalogue of known functions of the protein and its polymorphisms presented here will build a foundation for further speculations of the role of ECP, and ultimately the role of the eosinophil.
Appendix
Available only for authorised users
Literature
1.
Ehrlich P: Uber die specifischen Granulation des Blutes. Archiv fur Anatomie und Physiologie, Physiologische Abteilung. 1879
2.
Wardlaw AJ, Moqbel R, Kay AB: Eosinophils: biology and role in disease. Adv Immunol. 1995, 60: 151-266.PubMedCrossRef
3.
Kurashima K, Numata M, Yachie A, Sai Y, Ishizaka N, Fujimura M, Matsuda T, Ohkuma S: The role of vacuolar H(+)-ATPase in the control of intragranular pH and exocytosis in eosinophils. Lab Invest. 1996, 75 (5): 689-698.PubMed
4.
Neves JS, Weller PF: Functional extracellular eosinophil granules: novel implications in eosinophil immunobiology. Curr Opin Immunol. 2009, 21 (6): 694-699.PubMedPubMedCentralCrossRef
5.
6.
Peterson CG, Venge P: Purification and characterization of a new cationic protein--eosinophil protein-X (EPX)--from granules of human eosinophils. Immunology. 1983, 50 (1): 19-26.PubMedPubMedCentral
7.
Desser RK, Himmelhoch SR, Evans WH, Januska M, Mage M, Shelton E: Guinea pig heterophil and eosinophil peroxidase. Arch Biochem Biophys. 1972, 148 (2): 452-465.PubMedCrossRef
8.
Olsson I, Venge P, Spitznagel JK, Lehrer RI: Arginine-rich cationic proteins of human eosinophil granules: comparison of the constituents of eosinophilic and neutrophilic leukocytes. Lab Invest. 1977, 36 (5): 493-500.PubMed
9.
Iwasaki H, Mizuno S, Mayfield R, Shigematsu H, Arinobu Y, Seed B, Gurish MF, Takatsu K, Akashi K: Identification of eosinophil lineage-committed progenitors in the murine bone marrow. J Exp Med. 2005, 201 (12): 1891-1897.PubMedPubMedCentralCrossRef
10.
Mori Y, Iwasaki H, Kohno K, Yoshimoto G, Kikushige Y, Okeda A, Uike N, Niiro H, Takenaka K, Nagafuji K, et al: Identification of the human eosinophil lineage-committed progenitor: revision of phenotypic definition of the human common myeloid progenitor. J Exp Med. 2009, 206 (1): 183-193.PubMedPubMedCentralCrossRef
11.
Egesten A, Calafat J, Weller PF, Knol EF, Janssen H, Walz TM, Olsson I: Localization of granule proteins in human eosinophil bone marrow progenitors. Int Arch Allergy Immunol. 1997, 114 (2): 130-138.PubMedCrossRef
12.
Gruart V, Truong MJ, Plumas J, Zandecki M, Kusnierz JP, Prin L, Vinatier D, Capron A, Capron M: Decreased expression of eosinophil peroxidase and major basic protein messenger RNAs during eosinophil maturation. Blood. 1992, 79 (10): 2592-2597.PubMed
13.
Carlson M, Oberg G, Peterson C, Venge P: Releasability of human hypereosinophilic eosinophils is related to the density of the cells. Br J Haematol. 1994, 86 (1): 41-47.PubMedCrossRef
14.
Bystrom J, Tenno T, Hakansson L, Amin K, Trulson A, Hogbom E, Venge P: Monocytes, but not macrophages, produce the eosinophil cationic protein. Apmis. 2001, 109 (7-8): 507-516.PubMedCrossRef
15.
Monteseirin J, Vega A, Chacon P, Camacho MJ, El Bekay R, Asturias JA, Martinez A, Guardia P, Perez-Cano R, Conde J: Neutrophils as a novel source of eosinophil cationic protein in IgE-mediated processes. J Immunol. 2007, 179 (4): 2634-2641.PubMedCrossRef
16.
Sur S, Glitz DG, Kita H, Kujawa SM, Peterson EA, Weiler DA, Kephart GM, Wagner JM, George TJ, Gleich GJ, et al: Localization of eosinophil-derived neurotoxin and eosinophil cationic protein in neutrophilic leukocytes. J Leukoc Biol. 1998, 63 (6): 715-722.PubMed
17.
Bystrom J, Garcia RC, Hakansson L, Karawajczyk M, Moberg L, Soukka J, Venge P: Eosinophil cationic protein is stored in, but not produced by, peripheral blood neutrophils. Clin Exp Allergy. 2002, 32 (7): 1082-1091.PubMedCrossRef
18.
Handen JS, Rosenberg HF: Intronic enhancer activity of the eosinophil-derived neurotoxin (RNS2) and eosinophil cationic protein (RNS3) genes is mediated by an NFAT-1 consensus binding sequence. J Biol Chem. 1997, 272 (3): 1665-1669.PubMedCrossRef
19.
Rosenberg HF, Dyer KD, Tiffany HL, Gonzalez M: Rapid evolution of a unique family of primate ribonuclease genes. Nat Genet. 1995, 10 (2): 219-223.PubMedCrossRef
20.
Gleich GJ, Loegering DA, Bell MP, Checkel JL, Ackerman SJ, McKean DJ: Biochemical and functional similarities between human eosinophil-derived neurotoxin and eosinophil cationic protein: homology with ribonuclease. Proc Natl Acad Sci USA. 1986, 83 (10): 3146-3150.PubMedPubMedCentralCrossRef
21.
Rosenberg HF: Recombinant human eosinophil cationic protein. Ribonuclease activity is not essential for cytotoxicity. J Biol Chem. 1995, 270 (14): 7876-7881.PubMedCrossRef
22.
Boix E, Leonidas DD, Nikolovski Z, Nogues MV, Cuchillo CM, Acharya KR: Crystal structure of eosinophil cationic protein at 2.4 A resolution. Biochemistry. 1999, 38 (51): 16794-16801.PubMedCrossRef
23.
Sorrentino S, Glitz DG: Ribonuclease activity and substrate preference of human eosinophil cationic protein (ECP). FEBS Lett. 1991, 288 (1-2): 23-26.PubMedCrossRef
24.
Rosenberg HF, Ackerman SJ, Tenen DG: Human eosinophil cationic protein. Molecular cloning of a cytotoxin and helminthotoxin with ribonuclease activity. J Exp Med. 1989, 170 (1): 163-176.PubMedCrossRef
25.
Eriksson J, Woschnagg C, Fernvik E, Venge P: A SELDI-TOF MS study of the genetic and post-translational molecular heterogeneity of eosinophil cationic protein. J Leukoc Biol. 2007, 82 (6): 1491-1500.PubMedCrossRef
26.
Peterson CG, Jornvall H, Venge P: Purification and characterization of eosinophil cationic protein from normal human eosinophils. Eur J Haematol. 1988, 40 (5): 415-423.PubMedCrossRef
27.
Pous J, Mallorqui-Fernandez G, Peracaula R, Terzyan SS, Futami J, Tada H, Yamada H, Seno M, de Llorens R, Gomis-Ruth FX, et al: Three-dimensional structure of human RNase 1 delta N7 at 1.9 A resolution. Acta Crystallogr D Biol Crystallogr. 2001, 57 (Pt 4): 498-505.PubMedCrossRef
28.
Maeda T, Mahara K, Kitazoe M, Futami J, Takidani A, Kosaka M, Tada H, Seno M, Yamada H: RNase 3 (ECP) is an extraordinarily stable protein among human pancreatic-type RNases. J Biochem (Tokyo). 2002, 132 (5): 737-742.CrossRef
29.
Ulrich M, Petre A, Youhnovski N, Promm F, Schirle M, Schumm M, Pero RS, Doyle A, Checkel J, Kita H, et al: Post-translational tyrosine nitration of eosinophil granule toxins mediated by eosinophil peroxidase. J Biol Chem. 2008, 283 (42): 28629-28640.PubMedPubMedCentralCrossRef
30.
Young JD, Peterson CG, Venge P, Cohn ZA: Mechanism of membrane damage mediated by human eosinophil cationic protein. Nature. 1986, 321 (6070): 613-616.PubMedCrossRef
31.
Carreras E, Boix E, Rosenberg HF, Cuchillo CM, Nogues MV: Both aromatic and cationic residues contribute to the membrane-lytic and bactericidal activity of eosinophil cationic protein. Biochemistry. 2003, 42 (22): 6636-6644.PubMedCrossRef
32.
Carreras E, Boix E, Navarro S, Rosenberg HF, Cuchillo CM, Nogues MV: Surface-exposed amino acids of eosinophil cationic protein play a critical role in the inhibition of mammalian cell proliferation. Mol Cell Biochem. 2005, 272 (1-2): 1-7.PubMedCrossRef
33.
Fredens K, Dahl R, Venge P: In vitro studies of the interaction between heparin and eosinophil cationic protein. Allergy. 1991, 46 (1): 27-29.PubMedCrossRef
34.
Maeda T, Kitazoe M, Tada H, de Llorens R, Salomon DS, Ueda M, Yamada H, Seno M: Growth inhibition of mammalian cells by eosinophil cationic protein. Eur J Biochem. 2002, 269 (1): 307-316.PubMedCrossRef
35.
Fan TC, Fang SL, Hwang CS, Hsu CY, Lu XA, Hung SC, Lin SC, Chang MD: Characterization of molecular interactions between eosinophil cationic protein and heparin. J Biol Chem. 2008, 283 (37): 25468-25474.PubMedCrossRef
36.
Trulson A, Bystrom J, Engstrom A, Larsson R, Venge P: The functional heterogeneity of eosinophil cationic protein is determined by a gene polymorphism and post-translational modifications. Clin Exp Allergy. 2007, 37 (2): 208-218.PubMedCrossRef
37.
Yang D, Chen Q, Su SB, Zhang P, Kurosaka K, Caspi RR, Michalek SM, Rosenberg HF, Zhang N, Oppenheim JJ: Eosinophil-derived neurotoxin acts as an alarmin to activate the TLR2-MyD88 signal pathway in dendritic cells and enhances Th2 immune responses. J Exp Med. 2008, 205 (1): 79-90.PubMedPubMedCentralCrossRef
38.
Torrent M, Navarro S, Moussaoui M, Nogues MV, Boix E: Eosinophil cationic protein high-affinity binding to bacteria-wall lipopolysaccharides and peptidoglycans. Biochemistry. 2008, 47 (11): 3544-3555.PubMedCrossRef
39.
Torrent M, de la Torre BG, Nogues VM, Andreu D, Boix E: Bactericidal and membrane disruption activities of the eosinophil cationic protein are largely retained in an N-terminal fragment. Biochem J. 2009, 421 (3): 425-434.PubMedCrossRef
40.
Jonsson UB, Bystrom J, Stalenheim G, Venge P: Polymorphism of the eosinophil cationic protein-gene is related to the expression of allergic symptoms. Clin Exp Allergy. 2002, 32 (7): 1092-1095.PubMedCrossRef
41.
Rubin J, Zagai U, Blom K, Trulson A, Engstrom A, Venge P: The coding ECP 434(G > C) gene polymorphism determines the cytotoxicity of ECP but has minor effects on fibroblast-mediated gel contraction and no effect on RNase activity. J Immunol. 2009, 183 (1): 445-451.PubMedCrossRef
42.
Koh GC, Shek LP, Goh DY, Van Bever H, Koh DS: Eosinophil cationic protein: is it useful in asthma? A systematic review. Respir Med. 2007, 101 (4): 696-705.PubMedCrossRef
43.
Bjork A, Venge P, Peterson CG: Measurements of ECP in serum and the impact of plasma coagulation. Allergy. 2000, 55 (5): 442-448.PubMedCrossRef
44.
Peterson CG, Enander I, Nystrand J, Anderson AS, Nilsson L, Venge P: Radioimmunoassay of human eosinophil cationic protein (ECP) by an improved method. Establishment of normal levels in serum and turnover in vivo. Clin Exp Allergy. 1991, 21 (5): 561-567.PubMedCrossRef
45.
Peterson CG, Venge P: Interaction and complex-formation between the eosinophil cationic protein and alpha 2-macroglobulin. Biochem J. 1987, 245 (3): 781-787.PubMedPubMedCentralCrossRef
46.
LaMarre J, Wollenberg GK, Gonias SL, Hayes MA: Cytokine binding and clearance properties of proteinase-activated alpha 2-macroglobulins. Lab Invest. 1991, 65 (1): 3-14.PubMed
47.
Wardlaw AJ: Molecular basis for selective eosinophil trafficking in asthma: A multistep paradigm. J Allergy Clin Immunol. 1999, 104 (5): 917-926.PubMedCrossRef
48.
Amin K, Rinne J, Haahtela T, Simola M, Peterson CG, Roomans GM, Malmberg H, Venge P, Seveus L: Inflammatory cell and epithelial characteristics of perennial allergic and nonallergic rhinitis with a symptom history of 1 to 3 years' duration. J Allergy Clin Immunol. 2001, 107 (2): 249-257.PubMedCrossRef
49.
Amin K, Ludviksdottir D, Janson C, Nettelbladt O, Bjornsson E, Roomans GM, Boman G, Seveus L, Venge P: Inflammation and structural changes in the airways of patients with atopic and nonatopic asthma. BHR Group. Am J Respir Crit Care Med. 2000, 162 (6): 2295-2301.PubMedCrossRef
50.
Kato M, Kephart GM, Talley NJ, Wagner JM, Sarr MG, Bonno M, McGovern TW, Gleich GJ: Eosinophil infiltration and degranulation in normal human tissue. Anat Rec. 1998, 252 (3): 418-425.PubMedCrossRef
51.
Press MF, King WJ: Distribution of peroxidase and granulocytes in the human uterus. Lab Invest. 1986, 54 (2): 188-203.PubMed
52.
Gouon-Evans V, Lin EY, Pollard JW: Requirement of macrophages and eosinophils and their cytokines/chemokines for mammary gland development. Breast Cancer Res. 2002, 4 (4): 155-164.PubMedPubMedCentralCrossRef
53.
Leiferman KM, Peters MS, Gleich GJ: The eosinophil and cutaneous edema. J Am Acad Dermatol. 1986, 15 (3): 513-517.PubMedCrossRef
54.
Mishra A, Hogan SP, Lee JJ, Foster PS, Rothenberg ME: Fundamental signals that regulate eosinophil homing to the gastrointestinal tract. J Clin Invest. 1999, 103 (12): 1719-1727.PubMedPubMedCentralCrossRef
55.
Muller E: Localization of eosinophils in the thymus by the peroxidase reaction. Histochemistry. 1977, 52 (3): 273-279.PubMedCrossRef
56.
Malm-Erjefalt M, Greiff L, Ankerst J, Andersson M, Wallengren J, Cardell LO, Rak S, Persson CG, Erjefalt JS: Circulating eosinophils in asthma, allergic rhinitis, and atopic dermatitis lack morphological signs of degranulation. Clin Exp Allergy. 2005, 35 (10): 1334-1340.PubMedCrossRef
57.
Xu X, Hakansson L: Regulation of the release of eosinophil cationic protein by eosinophil adhesion. Clin Exp Allergy. 2000, 30 (6): 794-806.PubMedCrossRef
58.
Kato Y, Fujisawa T, Terada A, Iguchi K, Kamiya H: Mechanisms of eosinophil cationic protein release in the serum: role of adhesion molecules. Int Arch Allergy Immunol. 1999, 120 (Suppl 1): 60-64.PubMedCrossRef
59.
Takafuji S, Tadokoro K, Ito K, Nakagawa T: Release of granule proteins from human eosinophils stimulated with mast-cell mediators. Allergy. 1998, 53 (10): 951-956.PubMedCrossRef
60.
Kita H, Weiler DA, Abu-Ghazaleh R, Sanderson CJ, Gleich GJ: Release of granule proteins from eosinophils cultured with IL-5. J Immunol. 1992, 149 (2): 629-635.PubMed
61.
Takafuji S, Tadokoro K, Ito K: Effects of interleukin (IL)-3 and IL-5 on human eosinophil degranulation induced by complement components C3a and C5a. Allergy. 1996, 51 (8): 563-568.PubMedCrossRef
62.
Woschnagg C, Rubin J, Venge P: Eosinophil cationic protein (ECP) is processed during secretion. J Immunol. 2009, 183 (6): 3949-3954.PubMedCrossRef
63.
Shoji S, Kanazawa H, Hirata K, Kurihara N, Yoshikawa J: Clinical implication of protein levels of IL-5 in induced sputum in asthmatic patients. J Asthma. 1998, 35 (3): 243-249.PubMedCrossRef
64.
Davis MD, Plager DA, George TJ, Weiss EA, Gleich GJ, Leiferman KM: Interactions of eosinophil granule proteins with skin: limits of detection, persistence, and vasopermeabilization. J Allergy Clin Immunol. 2003, 112 (5): 988-994.PubMedCrossRef
65.
Lampinen M, Ronnblom A, Amin K, Kristjansson G, Rorsman F, Sangfelt P, Safsten B, Wagner M, Wanders A, Winqvist O, et al: Eosinophil granulocytes are activated during the remission phase of ulcerative colitis. Gut. 2005, 54 (12): 1714-1720.PubMedPubMedCentralCrossRef
66.
67.
Fujimoto K, Kubo K, Matsuzawa Y, Sekiguchi M: Eosinophil cationic protein levels in induced sputum correlate with the severity of bronchial asthma. Chest. 1997, 112 (5): 1241-1247.PubMedCrossRef
68.
Venge P, Bystrom J, Carlson M, Hakansson L, Karawacjzyk M, Peterson C, Seveus L, Trulson A: Eosinophil cationic protein (ECP): molecular and biological properties and the use of ECP as a marker of eosinophil activation in disease. Clin Exp Allergy. 1999, 29 (9): 1172-1186.PubMedCrossRef
69.
Kristjansson G, Venge P, Wanders A, Loof L, Hallgren R: Clinical and subclinical intestinal inflammation assessed by the mucosal patch technique: studies of mucosal neutrophil and eosinophil activation in inflammatory bowel diseases and irritable bowel syndrome. Gut. 2004, 53 (12): 1806-1812.PubMedPubMedCentralCrossRef
70.
Bartoli ML, Bacci E, Carnevali S, Cianchetti S, Dente FL, Di Franco A, Giannini D, Taccola M, Vagaggini B, Paggiaro PL: Clinical assessment of asthma severity partially corresponds to sputum eosinophilic airway inflammation. Respir Med. 2004, 98 (2): 184-193.PubMedCrossRef
71.
Koh YY, Kang H, Kim CK: Ratio of serum eosinophil cationic protein/blood eosinophil counts in children with asthma: comparison between acute exacerbation and clinical remission. Allergy Asthma Proc. 2003, 24 (4): 269-274.PubMed
72.
Tischendorf FW, Brattig NW, Lintzel M, Buttner DW, Burchard GD, Bork K, Muller M: Eosinophil granule proteins in serum and urine of patients with helminth infections and atopic dermatitis. Trop Med Int Health. 2000, 5 (12): 898-905.PubMedCrossRef
73.
Ooi CY, Day AS, Jackson R, Bohane TD, Tobias V, Lemberg DA: Eosinophilic esophagitis in children with celiac disease. J Gastroenterol Hepatol. 2008, 23 (7 Pt 1): 1144-1148.PubMedCrossRef
74.
Tischendorf FW, Brattig NW, Buttner DW, Pieper A, Lintzel M: Serum levels of eosinophil cationic protein, eosinophil-derived neurotoxin and myeloperoxidase in infections with filariae and schistosomes. Acta Trop. 1996, 62 (3): 171-182.PubMedCrossRef
75.
Kristjansson S, Bjarnarson SP, Wennergren G, Palsdottir AH, Arnadottir T, Haraldsson A, Jonsdottir I: Respiratory syncytial virus and other respiratory viruses during the first 3 months of life promote a local TH2-like response. J Allergy Clin Immunol. 2005, 116 (4): 805-811.PubMedCrossRef
76.
Karawajczyk M, Pauksen K, Peterson CG, Eklund E, Venge P: The differential release of eosinophil granule proteins. Studies on patients with acute bacterial and viral infections. Clin Exp Allergy. 1995, 25 (8): 713-719.PubMedCrossRef
77.
Niehaus MD, Gwaltney JM, Hendley JO, Newman MJ, Heymann PW, Rakes GP, Platts-Mills TA, Guerrant RL: Lactoferrin and eosinophilic cationic protein in nasal secretions of patients with experimental rhinovirus colds, natural colds, and presumed acute community-acquired bacterial sinusitis. J Clin Microbiol. 2000, 38 (8): 3100-3102.PubMedPubMedCentral
78.
Ashitani J, Yanagi S, Arimura Y, Sano A, Mukae H: Acute respiratory distress syndrome induced by rifampicin with high levels of neutrophil and eosinophil products in bronchoalveolar lavage fluid. Respiration. 2003, 70 (5): 541-543.PubMedCrossRef
79.
Motojima S, Frigas E, Loegering DA, Gleich GJ: Toxicity of eosinophil cationic proteins for guinea pig tracheal epithelium in vitro. Am Rev Respir Dis. 1989, 139 (3): 801-805.PubMedCrossRef
80.
Trautmann A, Schmid-Grendelmeier P, Kruger K, Crameri R, Akdis M, Akkaya A, Brocker EB, Blaser K, Akdis CA: T cells and eosinophils cooperate in the induction of bronchial epithelial cell apoptosis in asthma. J Allergy Clin Immunol. 2002, 109 (2): 329-337.PubMedCrossRef
81.
Zagai U, Dadfar E, Lundahl J, Venge P, Skold CM: Eosinophil cationic protein stimulates TGF-beta1 release by human lung fibroblasts in vitro. Inflammation. 2007, 30 (5): 153-160.PubMedCrossRef
82.
Kocak AK, Bor O, Yildiz B, Erdogan L, Us T: T-lymphocyte activation and the levels of eosinophilic cationic protein and interleukin-5 in asthmatic children with acute exacerbation and effect of glucocorticoid treatment. Allergy Asthma Proc. 2006, 27 (4): 371-377.PubMedCrossRef
83.
Marcucci F, Sensi L, Di Cara G, Salvatori S, Bernini M, Pecora S, Burastero SE: Three-year follow-up of clinical and inflammation parameters in children monosensitized to mites undergoing sub-lingual immunotherapy. Pediatr Allergy Immunol. 2005, 16 (6): 519-526.PubMedCrossRef
84.
Yamamoto H, Sedgwick JB, Vrtis RF, Busse WW: The effect of transendothelial migration on eosinophil function. Am J Respir Cell Mol Biol. 2000, 23 (3): 379-388.PubMedCrossRef
85.
Shi HZ, Humbles A, Gerard C, Jin Z, Weller PF: Lymph node trafficking and antigen presentation by endobronchial eosinophils. J Clin Invest. 2000, 105 (7): 945-953.PubMedPubMedCentralCrossRef
86.
Peterson CG, Skoog V, Venge P: Human eosinophil cationic proteins (ECP and EPX) and their suppressive effects on lymphocyte proliferation. Immunobiology. 1986, 171 (1-2): 1-13.PubMedCrossRef
87.
Kimata H, Yoshida A, Ishioka C, Jiang Y, Mikawa H: Inhibition of ongoing immunoglobulin production by eosinophil cationic protein. Clin Immunol Immunopathol. 1992, 64 (1): 84-88.PubMedCrossRef
88.
Kimata H, Yoshida A, Ishioka C, Jiang Y, Mikawa H: Eosinophil cationic protein inhibits immunoglobulin production and proliferation in vitro in human plasma cells. Cell Immunol. 1992, 141 (2): 422-432.PubMedCrossRef
89.
Sont JK, Han J, van Krieken JM, Evertse CE, Hooijer R, Willems LN, Sterk PJ: Relationship between the inflammatory infiltrate in bronchial biopsy specimens and clinical severity of asthma in patients treated with inhaled steroids. Thorax. 1996, 51 (5): 496-502.PubMedPubMedCentralCrossRef
90.
Gundel RH, Letts LG, Gleich GJ: Human eosinophil major basic protein induces airway constriction and airway hyperresponsiveness in primates. J Clin Invest. 1991, 87 (4): 1470-1473.PubMedPubMedCentralCrossRef
91.
Minai-Fleminger Y, Levi-Schaffer F: Mast cells and eosinophils: the two key effector cells in allergic inflammation. Inflamm Res. 2009, 58 (10): 631-638.PubMedCrossRef
92.
Zheutlin LM, Ackerman SJ, Gleich GJ, Thomas LL: Stimulation of basophil and rat mast cell histamine release by eosinophil granule-derived cationic proteins. J Immunol. 1984, 133 (4): 2180-2185.PubMed
93.
Okayama Y, el-Lati SG, Leiferman KM, Church MK: Eosinophil granule proteins inhibit substance P-induced histamine release from human skin mast cells. J Allergy Clin Immunol. 1994, 93 (5): 900-909.PubMedCrossRef
94.
Patella V, de Crescenzo G, Marino I, Genovese A, Adt M, Gleich GJ, Marone G: Eosinophil granule proteins activate human heart mast cells. J Immunol. 1996, 157 (3): 1219-1225.PubMed
95.
Luster AD, Tager AM: T-cell trafficking in asthma: lipid mediators grease the way. Nat Rev Immunol. 2004, 4 (9): 711-724.PubMedCrossRef
96.
Messmer EM, May CA, Stefani FH, Welge-Luessen U, Kampik A: Toxic eosinophil granule protein deposition in corneal ulcerations and scars associated with atopic keratoconjunctivitis. Am J Ophthalmol. 2002, 134 (6): 816-821.PubMedCrossRef
97.
Hohlfeld JM, Schmiedl A, Erpenbeck VJ, Venge P, Krug N: Eosinophil cationic protein alters pulmonary surfactant structure and function in asthma. J Allergy Clin Immunol. 2004, 113 (3): 496-502.PubMedCrossRef
98.
Trocme SD, Hallberg CK, Gill KS, Gleich GJ, Tyring SK, Brysk MM: Effects of eosinophil granule proteins on human corneal epithelial cell viability and morphology. Invest Ophthalmol Vis Sci. 1997, 38 (3): 593-599.PubMed
99.
Lundgren JD, Davey RT, Lundgren B, Mullol J, Marom Z, Logun C, Baraniuk J, Kaliner MA, Shelhamer JH: Eosinophil cationic protein stimulates and major basic protein inhibits airway mucus secretion. J Allergy Clin Immunol. 1991, 87 (3): 689-698.PubMedCrossRef
100.
Altman LC, Ayars GH, Baker C, Luchtel DL: Cytokines and eosinophil-derived cationic proteins upregulate intercellular adhesion molecule-1 on human nasal epithelial cells. J Allergy Clin Immunol. 1993, 92 (4): 527-536.PubMedCrossRef
101.
Chihara J, Yamamoto T, Kurachi D, Kakazu T, Higashimoto I, Nakajima S: Possible release of eosinophil granule proteins in response to signaling from intercellular adhesion molecule-1 and its ligands. Int Arch Allergy Immunol. 1995, 108 (Suppl 1): 52-54.PubMedCrossRef
102.
Chihara J, Urayama O, Tsuda A, Kakazu T, Higashimoto I, Yamada H: Eosinophil cationic protein induces insulin-like growth factor I receptor expression on bronchial epithelial cells. Int Arch Allergy Immunol. 1996, 111 (Suppl 1): 43-45.PubMedCrossRef
103.
Straumann A, Spichtin HP, Grize L, Bucher KA, Beglinger C, Simon HU: Natural history of primary eosinophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years. Gastroenterology. 2003, 125 (6): 1660-1669.PubMedCrossRef
104.
Dominguez-Ortega J, Perez-Bedmar J, Rodriguez-Jimenez B, Butron M, Kindelan C, Ledesma A: Eosinophilic esophagitis due to profilin allergy. J Investig Allergol Clin Immunol. 2009, 19 (4): 338-339.PubMed
105.
Minshall EM, Leung DY, Martin RJ, Song YL, Cameron L, Ernst P, Hamid Q: Eosinophil-associated TGF-beta1 mRNA expression and airways fibrosis in bronchial asthma. Am J Respir Cell Mol Biol. 1997, 17 (3): 326-333.PubMedCrossRef
106.
Cho JY, Miller M, Baek KJ, Han JW, Nayar J, Lee SY, McElwain K, McElwain S, Friedman S, Broide DH: Inhibition of airway remodeling in IL-5-deficient mice. J Clin Invest. 2004, 113 (4): 551-560.PubMedPubMedCentralCrossRef
107.
Zagai U, Lundahl J, Klominek J, Venge P, Skold CM: Eosinophil cationic protein stimulates migration of human lung fibroblasts in vitro. Scand J Immunol. 2009, 69 (4): 381-386.PubMedCrossRef
108.
Hernnas J, Sarnstrand B, Lindroth P, Peterson CG, Venge P, Malmstrom A: Eosinophil cationic protein alters proteoglycan metabolism in human lung fibroblast cultures. Eur J Cell Biol. 1992, 59 (2): 352-363.PubMed
109.
Solarewicz-Madejek K, Basinski TM, Crameri R, Akdis M, Akkaya A, Blaser K, Rabe KF, Akdis CA, Jutel M: T cells and eosinophils in bronchial smooth muscle cell death in asthma. Clin Exp Allergy. 2009, 39 (6): 845-855.PubMedCrossRef
110.
Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, et al: A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003, 348 (13): 1201-1214.PubMedCrossRef
111.
Plotz SG, Abeck D, Seitzer U, Hein R, Ring J: UVA1 for hypereosinophilic syndrome. Acta Derm Venereol. 2000, 80 (3): 221-PubMedCrossRef
112.
Park YJ, Oh EJ, Park JW, Kim M, Han K: Plasma eosinophil cationic protein, interleukin-5, and ECP/Eo count ratio in patients with various eosinophilic diseases. Ann Clin Lab Sci. 2006, 36 (3): 262-266.PubMed
113.
Ogbogu PU, Bochner BS, Butterfield JH, Gleich GJ, Huss-Marp J, Kahn JE, Leiferman KM, Nutman TB, Pfab F, Ring J, et al: Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol. 2009, 124 (6): 1319-1325. e1313.PubMedPubMedCentralCrossRef
114.
Plager DA, Davis MD, Andrews AG, Coenen MJ, George TJ, Gleich GJ, Leiferman KM: Eosinophil ribonucleases and their cutaneous lesion-forming activity. J Immunol. 2009, 183 (6): 4013-4020.PubMedPubMedCentralCrossRef
115.
Yamada T, Shinohara K, Katsuki K: A case of idiopathic hypereosinophilic syndrome complicated with disseminated intravascular coagulation. Am J Hematol. 1998, 59 (1): 100-101.PubMedCrossRef
116.
Leiferman KM, Gleich GJ: Hypereosinophilic syndrome: case presentation and update. J Allergy Clin Immunol. 2004, 113 (1): 50-58.PubMedCrossRef
117.
Venge P, Dahl R, Hallgren R: Enhancement of factor XII dependent reactions by eosinophil cationic protein. Thromb Res. 1979, 14 (4-5): 641-649.PubMedCrossRef
118.
Sugihara R, Kumamoto T, Ito T, Ueyama H, Toyoshima I, Tsuda T: Human muscle protein degradation in vitro by eosinophil cationic protein (ECP). Muscle Nerve. 2001, 24 (12): 1627-1634.PubMedCrossRef
119.
Tai PC, Ackerman SJ, Spry CJ, Dunnette S, Olsen EG, Gleich GJ: Deposits of eosinophil granule proteins in cardiac tissues of patients with eosinophilic endomyocardial disease. Lancet. 1987, 1 (8534): 643-647.PubMedCrossRef
120.
Frickhofen N, Marker-Hermann E, Reiter A, Walz C, Jung B, Bauer H, Hochhaus A: Complete molecular remission of chronic eosinophilic leukemia complicated by CNS disease after targeted therapy with imatinib. Ann Hematol. 2004, 83 (7): 477-480.PubMedCrossRef
121.
Fredens K, Dahl R, Venge P: The Gordon phenomenon induced by the eosinophil cationic protein and eosinophil protein X. J Allergy Clin Immunol. 1982, 70 (5): 361-366.PubMedCrossRef
122.
123.
Trulson A, Nilsson S, Venge P: The eosinophil granule proteins in serum, but not the oxidative metabolism of the blood eosinophils, are increased in cancer. Br J Haematol. 1997, 98 (2): 312-314.PubMedCrossRef
124.
Lose G, Frandsen B: Eosinophil cationic protein in urine in patients with urinary bladder tumors. Urol Res. 1989, 17 (5): 295-297.PubMedCrossRef
125.
Navarro S, Aleu J, Jimenez M, Boix E, Cuchillo CM, Nogues MV: The cytotoxicity of eosinophil cationic protein/ribonuclease 3 on eukaryotic cell lines takes place through its aggregation on the cell membrane. Cell Mol Life Sci. 2008, 65 (2): 324-337.PubMedCrossRef
126.
Al-Owais MM, Hesse L, Talbot SJ, Adams DJ: Human non-pregnancy ribonuclease with anti-Kaposi's sarcoma activity. Cancer Lett. 2002, 176 (2): 183-189.PubMedCrossRef
127.
Klion AD, Nutman TB: The role of eosinophils in host defense against helminth parasites. J Allergy Clin Immunol. 2004, 113 (1): 30-37.PubMedCrossRef
128.
Kouriba B, Traore HA, Dabo A, Sangare L, Guindo H, Keita AS, Reimert CM, van Dam GJ, Deelder AM, Doumbo O, et al: Urinary disease in 2 Dogon populations with different exposure to Schistosoma haematobium infection: progression of bladder and kidney diseases in children and adults. J Infect Dis. 2005, 192 (12): 2152-2159.PubMedCrossRef
129.
Gutierrez-Pena EJ, Knab J, Buttner DW: Immunoelectron microscopic evidence for release of eosinophil granule matrix protein onto microfilariae of Onchocerca volvulus in the skin after exposure to amocarzine. Parasitol Res. 1998, 84 (8): 607-615.PubMedCrossRef
130.
Wildenburg G, Darge K, Knab J, Tischendorf FW, Bonow I, Buttner DW: Lymph nodes of onchocerciasis patients after treatment with ivermectin: reaction of eosinophil granulocytes and their cationic granule proteins. Trop Med Parasitol. 1994, 45 (2): 87-96.PubMed
131.
McLaren DJ, Peterson CG, Venge P: Schistosoma mansoni: further studies of the interaction between schistosomula and granulocyte-derived cationic proteins in vitro. Parasitology. 1984, 88 (Pt 3): 491-503.PubMedCrossRef
132.
Hamann KJ, Gleich GJ, Checkel JL, Loegering DA, McCall JW, Barker RL: In vitro killing of microfilariae of Brugia pahangi and Brugia malayi by eosinophil granule proteins. J Immunol. 1990, 144 (8): 3166-3173.PubMed
133.
Molina HA, Kierszenbaum F, Hamann KJ, Gleich GJ: Toxic effects produced or mediated by human eosinophil granule components on Trypanosoma cruzi. Am J Trop Med Hyg. 1988, 38 (2): 327-334.PubMed
134.
Yousefi S, Gold JA, Andina N, Lee JJ, Kelly AM, Kozlowski E, Schmid I, Straumann A, Reichenbach J, Gleich GJ, et al: Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense. Nat Med. 2008, 14 (9): 949-953.PubMedCrossRef
135.
Lehrer RI, Szklarek D, Barton A, Ganz T, Hamann KJ, Gleich GJ: Antibacterial properties of eosinophil major basic protein and eosinophil cationic protein. J Immunol. 1989, 142 (12): 4428-4434.PubMed
136.
Grunberg K, Smits HH, Timmers MC, de Klerk EP, Dolhain RJ, Dick EC, Hiemstra PS, Sterk PJ: Experimental rhinovirus 16 infection. Effects on cell differentials and soluble markers in sputum in asthmatic subjects. Am J Respir Crit Care Med. 1997, 156 (2 Pt 1): 609-616.PubMedCrossRef
137.
Garofalo R, Kimpen JL, Welliver RC, Ogra PL: Eosinophil degranulation in the respiratory tract during naturally acquired respiratory syncytial virus infection. J Pediatr. 1992, 120 (1): 28-32.PubMedCrossRef
138.
Dyer KD, Percopo CM, Fischer ER, Gabryszewski SJ, Rosenberg HF: Pneumoviruses infect eosinophils and elicit MyD88-dependent release of chemoattractant cytokines and interleukin-6. Blood. 2009, 114 (13): 2649-2656.PubMedPubMedCentralCrossRef
139.
Domachowske JB, Dyer KD, Adams AG, Leto TL, Rosenberg HF: Eosinophil cationic protein/RNase 3 is another RNase A-family ribonuclease with direct antiviral activity. Nucleic Acids Res. 1998, 26 (14): 3358-3363.PubMedPubMedCentralCrossRef
140.
Domachowske JB, Dyer KD, Bonville CA, Rosenberg HF: Recombinant human eosinophil-derived neurotoxin/RNase 2 functions as an effective antiviral agent against respiratory syncytial virus. J Infect Dis. 1998, 177 (6): 1458-1464.PubMedCrossRef
141.
Zhang J, Rosenberg HF: Sequence variation at two eosinophil-associated ribonuclease loci in humans. Genetics. 2000, 156 (4): 1949-1958.PubMedPubMedCentral
142.
Noguchi E, Iwama A, Takeda K, Takeda T, Kamioka M, Ichikawa K, Akiba T, Arinami T, Shibasaki M: The promoter polymorphism in the eosinophil cationic protein gene and its influence on the serum eosinophil cationic protein level. Am J Respir Crit Care Med. 2003, 167 (2): 180-184.PubMedCrossRef
143.
Jonsson UB, Bystrom J, Stalenheim G, Venge P: A (G- > C) transversion in the 3' UTR of the human ECP (eosinophil cationic protein) gene correlates to the cellular content of ECP. J Leukoc Biol. 2006, 79 (4): 846-851.PubMedCrossRef
144.
Munthe-Kaas MC, Gerritsen J, Carlsen KH, Undlien D, Egeland T, Skinningsrud B, Torres T, Carlsen KL: Eosinophil cationic protein (ECP) polymorphisms and association with asthma, s-ECP levels and related phenotypes. Allergy. 2007, 62 (4): 429-436.PubMedCrossRef
145.
Kang I, An XH, Oh YK, Lee SH, Jung HM, Chae SC, Lee JH: Identification of polymorphisms in the RNase3 gene and the association with allergic rhinitis. Eur Arch Otorhinolaryngol. 2010, 267 (3): 391-395.PubMedCrossRef
146.
Pereira MC, Oliveira DT, Olivieri EH, Rogatto SR, Carvalho AL, Landman G, Kowalski LP: The 434(G > C) polymorphism in the eosinophil cationic protein gene and its association with tissue eosinophilia in oral squamous cell carcinomas. J Oral Pathol Med. 2010, 39 (1): 56-62.PubMedCrossRef
147.
Kim YJ, Kumaraswami V, Choi E, Mu J, Follmann DA, Zimmerman P, Nutman TB: Genetic polymorphisms of eosinophil-derived neurotoxin and eosinophil cationic protein in tropical pulmonary eosinophilia. Am J Trop Med Hyg. 2005, 73 (1): 125-130.PubMed
148.
Eriksson J, Reimert CM, Kabatereine NB, Kazibwe F, Ireri E, Kadzo H, Eltahir HB, Mohamed AO, Vennervald BJ, Venge P: The 434(G > C) polymorphism within the coding sequence of Eosinophil Cationic Protein (ECP) correlates with the natural course of Schistosoma mansoni infection. Int J Parasitol. 2007, 37 (12): 1359-1366.PubMedCrossRef
149.
Luster AD, Greenberg SM, Leder P: The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. J Exp Med. 1995, 182 (1): 219-231.PubMedCrossRef
150.
Leckie MJ, ten Brinke A, Khan J, Diamant Z, O'Connor BJ, Walls CM, Mathur AK, Cowley HC, Chung KF, Djukanovic R, et al: Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 2000, 356 (9248): 2144-2148.PubMedCrossRef
151.
Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, Hargreave FE, O'Byrne PM: Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009, 360 (10): 985-993.PubMedCrossRef
152.
Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding P, Green RH, Wardlaw AJ, et al: Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009, 360 (10): 973-984.PubMedPubMedCentralCrossRef
153.
Tarodo de la Fuente P, Romagnoli M, Carlsson L, Godard P, Bousquet J, Chanez P: Eosinophilic inflammation assessed by induced sputum in corticosteroid-dependent asthma. Respir Med. 1999, 93 (3): 183-189.PubMedCrossRef
154.
Yamada T, Tani Y, Nakanishi H, Taguchi R, Arita M, Arai H: Eosinophils promote resolution of acute peritonitis by producing proresolving mediators in mice. FASEB J.
155.
Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, O'Neill LA, Perretti M, Rossi AG, Wallace JL: Resolution of inflammation: state of the art, definitions and terms. FASEB J. 2007, 21 (2): 325-332.PubMedPubMedCentralCrossRef
156.
Reimert CM, Fitzsimmons CM, Joseph S, Mwatha JK, Jones FM, Kimani G, Hoffmann KF, Booth M, Kabatereine NB, Dunne DW, et al: Eosinophil activity in Schistosoma mansoni infections in vivo and in vitro in relation to plasma cytokine profile pre- and posttreatment with praziquantel. Clin Vaccine Immunol. 2006, 13 (5): 584-593.PubMedPubMedCentralCrossRef
157.
Brightling CE, Ward R, Woltmann G, Bradding P, Sheller JR, Dworski R, Pavord ID: Induced sputum inflammatory mediator concentrations in eosinophilic bronchitis and asthma. Am J Respir Crit Care Med. 2000, 162 (3 Pt 1): 878-882.PubMedCrossRef
158.
Klimek L, Rasp G: Norm values for eosinophil cationic protein in nasal secretions: influence of specimen collection. Clin Exp Allergy. 1999, 29 (3): 367-374.PubMedCrossRef
159.
Vancheri C, Mastruzzo C, Armato F, Tomaselli V, Magri S, Pistorio MP, LaMicela M, D'Amico L, Crimi N: Intranasal heparin reduces eosinophil recruitment after nasal allergen challenge in patients with allergic rhinitis. J Allergy Clin Immunol. 2001, 108 (5): 703-708.PubMedCrossRef
160.
Bonini S, Magrini L, Rotiroti G, Lambiase A, Tomassini M, Rumi C: The eosinophil and the eye. Allergy. 1997, 52 (34 Suppl): 44-47.PubMedCrossRef
161.
Metadata
Title
Analysing the eosinophil cationic protein - a clue to the function of the eosinophil granulocyte
Authors
Jonas Bystrom
Kawa Amin
David Bishop-Bailey
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2011
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/1465-9921-12-10

Other articles of this Issue 1/2011

Respiratory Research 1/2011 Go to the issue

Research

Real time analysis of β2-adrenoceptor-mediated signaling kinetics in Human Primary Airway Smooth Muscle Cells reveals both ligand and dose dependent differences

Research

Protease-activated receptor 2 activation of myeloid dendritic cells regulates allergic airway inflammation

Research

High blood pressure, antihypertensive medication and lung function in a general adult population

Research

Increase of nitrosative stress in patients with eosinophilic pneumonia

Research

Altered surfactant homeostasis and recurrent respiratory failure secondary to TTF-1 nuclear targeting defect

Research

Immunodetection of occult eosinophils in lung tissue biopsies may help predict survival in acute lung injury

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits